Combination chemotherapy versus temozolomide for patients with methylated MGMT (m-MGMT) glioblastoma: results of computational biological modeling to predict the magnitude of treatment benefit

Michael Castro1,2,3 · Anusha Pampana2,3 · Aftab Alam2,3 · Rajan Parashar2,3 · Swaminathan Rajagopalan2,3 · Deepak Anil Lala2,3 · Kunal Ghosh Ghosh Roy2,3 · Sayani Basu2,3 · Annapoorna Prakash2,3 · Prashant Nair2,3 · Vishwas Joseph2,3 · Ashish Agarwal2,3 · Poornachandra G2,3 · Liptimayee Behura2,3 · Shruthi Kulkarni2,3 · Nikita Ray Choudhary2,3 · Shweta Kapoor2,3

Received: 27 April 2021 / Accepted: 25 May 2021 / Published online: 8 June 2021
© The Author(s) 2021

Abstract

Background A randomized trial in glioblastoma patients with methylated-MGMT (m-MGMT) found an improvement in median survival of 16.7 months for combination therapy with temozolomide (TMZ) and lomustine, however the approach remains controversial and relatively under-utilized. Therefore, we sought to determine whether comprehensive genomic analysis can predict which patients would derive large, intermediate, or negligible benefits from the combination compared to single agent chemotherapy.

Methods Comprehensive genomic information from 274 newly diagnosed patients with methylated-MGMT glioblastoma (GBM) was downloaded from TCGA. Mutation and copy number changes were input into a computational biologic model to create an avatar of disease behavior and the malignant phenotypes representing hallmark behavior of cancers. In silico responses to TMZ, lomustine, and combination treatment were biosimulated. Efficacy scores representing the effect of treatment for each treatment strategy were generated and compared to each other to ascertain the differential benefit in drug response.

Results Differential benefits for each drug were identified, including strong, modest-intermediate, negligible, and deleterious (harmful) effects for subgroups of patients. Similarly, the benefits of combination therapy ranged from synergy, little or negligible benefit, and deleterious effects compared to single agent approaches.

Conclusions The benefit of combination chemotherapy is predicted to vary widely in the population. Biosimulation appears to be a useful tool to address the disease heterogeneity, drug response, and the relevance of particular clinical trials observations to individual patients. Biosimulation has potential to spare some patients the experience of over-treatment while identifying patients uniquely situated to benefit from combination treatment. Validation of this new artificial intelligence tool is needed.

Keywords Computational biological modeling · Biosimulation · Precision medicine · Glioblastoma (GBM) · O6-methylguanine-DNA methyl-transferase (MGMT) · Artificial intelligence (AI)

This study was previously presented in abstract form at Proceedings of ASCO 2020. Castro MP, et al. Journal of Clinical Oncology 2020 38:15_suppl, e14501-e14501

Michael Castro
michael.castro@personalizedcancermedicine.us

1 Personalized Cancer Medicine PLLC, 1735 S Hayworth Ave., Los Angeles, CA, USA
2 Cellworks Group, Inc., S. San Francisco, CA, USA
3 Cellworks Group, Inc., Bangalore, India

Abbreviations

ATM ATM serine/threonine kinase
ATR Ataxia telangiectasia and Rad3-related protein
BER Base excision repair
CBM Computational biological modeling
EZH2 Enhancer of zeste homolog-2
GBM Glioblastoma
HOXA10 Homeobox protein A-10
IDH1 Isocitrate dehydrogenase-1
HRD Homologous recombination repair deficiency
HRR  Homologous recombination repair  
KMT2  Lysine methyltransferase-2  
MGMT  O6-methylguanine-DNA methyl-transferase  
MMR  Mismatch repair  
MMRD  Mismatch repair deficiency  
NHEJ  Non-homologous end joining  
PARP  Poly ADP-ribose phosphorylase  
STAG2  Cohesin subunit SA-2  
TCGA  The Cancer Genome Atlas  
TMZ  Temozolomide  

Background

In the landmark trial by Stupp and colleagues in glioblastoma (GBM), adjuvant temozolomide (TMZ) chemotherapy decreased the death rate compared to radiation therapy alone by 37% and in 2005 became the standard of care for newly diagnosed patients [1]. By alkylating guanine residues, TMZ induces futile DNA mismatch repair that introduces single-stranded breaks resulting in replication fork arrest and cell death. The dominant but by no means only mechanism of TMZ resistance is caused by the DNA repair enzyme O6-methylguanine-DNA methyl-transferase (MGMT) which removes alkylated guanine bases to counter the lethal effects of the drug. The MGMT gene is subject to epigenetic regulation via methylation which silences its transcription. Hence, cancers with MGMT methylation (m-MGMT) tend to be highly responsive to TMZ with an increase in median survival of approximately six and one-half months compared to less than one month for unmethylated-MGMT (u-MGMT) cancers [2].

For patients with m-MGMT, efforts to build on the benefits of TMZ have explored combination chemotherapy regimens with the addition of lomustine to the TMZ backbone. A single arm, phase II trial (UKT-03) evaluated TMZ plus lomustine in newly diagnosed GBM patients revealed a median survival of 23 months, considerably better than the historical experience of 14.6 months [3]. Larger benefits accrued in the m-MGMT patients with a 2-year survival of 75% compared to 20% for u-MGMT patients, and median survival of not reached and 12.6 months, respectively. This led to the Nordic phase III trial (NOA-9) in newly diagnosed, m-MGMT GBM which randomized 141 patients to standard therapy (RT-TMZ followed by adjuvant TMZ) or experimental therapy with radiation alone followed by lomustine and TMZ every 6 weeks [4]. A striking superiority for the combination was observed for overall survival: 48.1 vs. 31.4 months for single agent TMZ (hazard ratio [HR] 0.60, 95% CI 0.35–1.03, p = 0.0492). A significant overall survival difference was also found in a secondary analysis of the intention-to-treat population (n = 141, HR 0.60, 95% CI 0.35–1.03, p = 0.0432). However, neurooncologists are often unwilling to prescribe combination therapy citing the small study size, delayed separation of the progression free survival curves, and increased toxicity in the combination arm [5].

Nevertheless, combination therapy may represent a survival opportunity for some patients and raises the question whether deeper genomic interrogation can identify the magnitude of benefit for combination treatment compared to single agent chemotherapy. Besides MGMT, differential sensitivity to both TMZ and lomustine is based on combinations of DNA repair abnormalities, impaired DNA checkpoints, epigenetic dysregulation, and oncogenic signaling pathways has been described [6–21]. These insights suggest we should be able to do a better job of stratifying patients by incorporating a more complete molecular diagnosis into therapeutic decision making. At the same time, the complexity of integrating the consequences of dozens of genomic abnormalities governing growth, apoptosis, and DNA repair is daunting. Accordingly, biosimulation based on comprehensive signaling pathway impact analysis utilizes computational biology modeling (CBM) of nearly 4,000 proteins. A virtual avatar of the patient’s cancer can be generated from comprehensive genomic inputs that permits an interrogation of the disease network regarding the impact size of various drug combinations on the hallmark behaviors of cancer. CBM incorporates DNA repair pathways (i.e., BER, MMR, HRR, NHEJ), apoptosis, survival, proliferation, oxidative stress, DNA checkpoints, receptor tyrosine kinases, transcription factors, and the TP53, NFkB, and hedgehog pathways. CBM has demonstrated high positive and negative predictive value (~ 90%) for predicting clinical outcomes in patients with low grade glioma, [22] glioblastoma [23, 24] and recently has received increasing attention for cancers that pose challenges to the development of new treatment approaches [21, 22, 25]. In a population of 100 patients with glioblastoma, biosimulation of treatment response was found to be strongly predictive of disease free survival (p=0.0266) and overall survival (p=0.0125), offering evidence that validates biosimulation [26]. Accordingly, we sought to assess the anticipated outcomes of m-MGMT GBM patients treated with either TMZ, lomustine, or the combination. As such the study was undertaken to assess the landscape of predicted responses based on comprehensive molecular diagnosis, but does not set out to validate the predictions with individual survival outcomes.

Materials and methods

Patient genomic information

The myCare -015 cohort consisted of adult patients more than 18 years of age with newly diagnosed m-MGMT GBM.
Mutation and copy number information was downloaded from TCGA (N = 274) from https://www.cbioportal.org/.

**Details of CBM and in silico modeling approach**

Biosimulation derives the signaling pathway impact from the totality of genomic aberrations represented by mutations and copy number aberrations to determine the consequences for hallmark behaviors of cancer, including proliferation, apoptosis, oxidative stress, immune evasion, etc. and a composite malignant phenotype represented by cell number (See Supplementary Sect. 1 for additional details).

For each patient, treatment efficacy scores (Teff) were computed for TMZ, lomustine, and the combination of both drugs based on their ability to reverse the phenotypic changes driving disease progression (i.e. proliferation) and to produce cell death (i.e. DNA damage, reactive oxygen species, survival, apoptotic blockade). In essence, computational modeling of genomic aberrations and the disregulated signaling pathways that follow permits a quantitative determination of various phenotypic behaviors of each individual’s cancer. The magnitude of divergence of each phenotype from the healthy cell characterizes the disease state and drug response for each patient which varies across the population according to the genomic abnormalities represented in the model. For example, some patients’ cancers are characterized by homologous recombination repair deficiency or DNA checkpoint defects which enhance responsiveness to chemotherapy. Others have mismatch repair deficits that compromises the benefit of temozolomide. Some patients have epigenetic aberrations that result in a highly proliferative cancer, while others may have signaling pathway dysregulation leading to a greater defect in apoptosis or enhancement of survival. Still others have upregulated multidrug resistance pumps that eliminate chemotherapy from the cell. In most cases, patients have multiple abnormalities which alter drug response in complex ways.

Once the disease avatar has been created, the interaction of temozolomide, lomustine, and the combination of both drugs with the unique disease network of each cancer is biosimulated to determine the quantitative impact of treatment on the various disease phenotypes. CBM integrates the sum of these interactions across the each patient’s disease network to produce a measurement of the extent to which the disease drivers are defeated by the treatment. In this way, CBM measures the degree of drug resistance and sensitivity in each patient, the basis of which varies considerably in the population.

The composite phenotype, Teff, denoting cell number represents the product of the individual phenotypic behaviors. As such, Teff represents the simulated impact on tumor growth caused by each therapy under consideration. Low Teff (< 30) represents lack of treatment efficacy. Higher Teff scores represent a collapse of phenotypic behaviors that represent the disease state. Teff > 80 indicates an exceptional responder. Teff < 0 suggests the treatment accelerates the disease state.

**Results**

**Patient characteristics**

The genomic abnormalities comprising the inputs to the model are shown in Table 1. The distribution of abnormalities is shown in Supplementary Fig. 1. Altogether 207 of 274 m-MGMT cancers were successfully modeled. The causes of disease induction failure are shown in Fig. 1.

**Efficacy predictions for single agent TMZ and lomustine**

We compared Teff for TMZ alone, lomustine alone, and the combination of TMZ and lomustine. As expected for this m-MGMT group, almost all patients had predicted to benefit from TMZ to some degree (Range: Teff = 25 to 81.78%). However, four patients had negative Teff values indicating anti-therapeutic or deleterious effect of TMZ due to the presence of mismatch repair deficiency (MMRD) which generates hypermutation without inducing lethality. Among patients with positive Teff values, the magnitude of TMZ benefit varied by approximately 4.5-fold (Range: Teff = 17–78%). (Supplementary Fig. 1A) Interestingly, in this population of m-MGMT patients, lomustine showed substantial efficacy (Range: Teff = 20.8–82.6%). (Supplementary Fig. 1B). Comparing the two drugs head to head, 120 (57.9%) patients had higher efficacy scores from lomustine compared to TMZ as single agents. But the opposite was true for 38 (18.4%) patients who had better efficacy scores from TMZ. Roughly equivalent benefits were observed (i.e. within 5 efficacy points of each other) in 49 (23.6%) patients. (Fig. 2).

**Efficacy predictions for combination TMZ plus lomustine**

The TMZ and lomustine combination generated positive Teff values for all patients. This included the patients with negative Teff arising from MMRD, implying that lomustine can rescue these patients from the adverse impact of TMZ in this setting. In general, the combination of TMZ and lomustine showed greater Teff values than TMZ alone (Range: Teff = 32.44–99.99%). (Supplementary Fig. 2) A majority of patients achieved Teff of approximately 78–86%, a finding supportive of the central conclusion of NOA-09.

We determined ΔTeff, the incremental benefit from the addition of combination therapy vs. TMZ alone
Table 1  Genomic abnormalities identified among 274 patients with MGMT-methylated GBM

| Pathway                                       | Gene          | Incidence |
|-----------------------------------------------|---------------|-----------|
| IDH                                           | IDH1          | 21 (10.1%)|
| Homologous recombination repair deficiency (HRD) | BRCA1         | 8 (3.9%)  |
|                                               | BRCA2         | 62 (30.0%)|
|                                               | both BRCA1 and BRCA2 | 4 (1.9%) |
|                                               | PALB2         | 21 (10.1%)|
|                                               | FANCA-D       | 40 (19.3%)|
|                                               | RAD50/51      | 51 (24.6%)|
| DNA checkpoints                                | ATM           | 37 (17.9%)|
|                                               | ATR           | 15 (7.2%) |
|                                               | both ATM and ATR | 4 (1.9%) |
| Base excision repair                           | APEX1         | 49 (23.7%)|
|                                               | ALKBH2/3      | 48 (23.2%)|
|                                               | LIG4          | 45 (21.7%)|
|                                               | XRCC3         | 44 (21.3%)|
|                                               | POLB          | 15 (7.2%) |
| Mismatch repair deficiency (MMRD)             | 2 genes       | 10 (4.8%) |
|                                               | 1 gene        | 9 (4.3%)  |
| TP53 abnormalities                             | 17p deletion  | 15 (7.2%) |
|                                               | TP53 mutation | 61 (29.5%)|
| Hedgehog pathway abnormalities                | SUFU deletion | 168 (81.2%)|
|                                               | GLI amp       | 24 (11.6%)|
| NF-κB pathway activation                      | NFKBIA deletion | 40 (19.3%)|
| Mitosis abnormalities                          | STAG2 deletion | 30 (14.5%)|
| Epigenetic driver abnormality                 | EP300         | 62 (30.0%)|
|                                               | KMT2A-D       | 50 (24.2%)|
|                                               | CREBBP        | 16 (7.7%) |

**HOXA10**

---

**Fig. 1** TCGA patients available for analysis. A minimum requirement of three genomic aberrations is needed to enable actionable insights and predictions (15/67). In most cases it was only one mutation that was reported and hence these patients were not included in the analysis. Biosimulation of the malignant phenotype, also referred to as “disease induction,” requires a two-fold increase in the hallmark behaviors such as cell number, proliferation, and viability, but was not achieved in the 11/67. Finally, biosimulation requires that the disease cell comes to a steady state. However, in some cases the drug interacts with the disease network in a manner that generates positive feedback loops that prevent a steady state from being achieved (41/67).
varied substantially across the population (Range: $T_{\text{eff}}$ 0.11–95.22%). (Supplementary Fig. 2A) The rectangular shape of the histogram suggests that the benefit of treatment is unpredictable, ranging from deriving nothing at all to profound benefit from the combination:

- 24 (11.6%) achieved greater than 99% efficacy, even with $T_{\text{eff}}$ starting as low as 34% from TMZ alone.
- 9 (4.3%) would be predicted to have less than 2% increase in efficacy from the addition of lomustine.
- 38 (18.4%) would achieve less than an 11% gain from the addition of lomustine deriving little benefit from the addition of lomustine.
- 70 (33.8%) had increased $T_{\text{eff}}$ of 11–33% from the combination, a modest benefit.
- 99 (47.8%) had greater than 33% increment in $T_{\text{eff}}$, thus deriving substantial benefit from the combination.

We also determined $\Delta T_{\text{eff}}$ for the incremental benefit of adding combination therapy vs. lomustine alone where the combination was deleterious for some and beneficial for others (Range: $T_{\text{eff}}$ −50.1 to +50.3%). (Supplementary Fig. 2B) To our surprise, the addition of TMZ detracted from $T_{\text{eff}}$ of lomustine alone for 33 (15.9%) patients. An additional 37 (17.9%) patients had a negligible benefit from the addition of TMZ, while 64 (30.9%) had only a minimal or modest benefit, and the remainder 73 (35.4%) derived a substantial increment in phenotype response from the combination.

We plotted the benefit for 1) combination therapy v. TMZ alone and 2) combination therapy v. lomustine alone (Fig. 3). The diagonal line on these graphs represents equivalence for the combination (shown on the abscissa) compared to each single agent (shown on the ordinate). The horizontal distance of each point to the diagonal gives the magnitude of anticipated incremental benefit of combination therapy (Fig. 3). Patients with values close to the diagonal should not be treated with combination chemotherapy. On the other hand, a patient who falls far right of the diagonal appears ideally suited to receive combination treatment. Impressively, about one in nine patients are predicted to derive greater than 99% efficacy from combination treatment. On the other hand, for patients whose values fall in an intermediate range, clinical judgment would be needed to weigh the risk of a marginal benefit against the increased toxicity. Surprisingly, lomustine alone outperformed combination treatment in 33 (15.9%) of patients, implying that the addition of TMZ would be harmful compared to single agent lomustine and therefore contraindicated. Examples of four different response scenarios are shown for individual patients in Fig. 4 and suggest that patients should be managed with all of the treatment strategies depending on the results of biosimulation. The generalized proposition about the superiority of combination therapy for $m$-MGMT GBM though true for the population as a whole was not uniformly supported for individual patients.
Fig. 3 Biosimulation of drug efficacy ($T_{eff}$) for combination v. single agent chemotherapy. Each point represents biosimulation results for a single patient. The diagonal line represents therapeutic equivalence. 

A $T_{eff}$ scores for TMZ v. TMZ + lomustine. The horizontal distance from each point to the diagonal gives the magnitude of incremental benefit from the addition of lomustine compared to TMZ alone.

B $T_{eff}$ scores for lomustine v. TMZ + lomustine. The horizontal distance from each point to the diagonal gives the magnitude of incremental benefit (to the right) or decremental harm (to the left) from the addition of TMZ to lomustine compared to lomustine alone. Some patients are predicted to achieve 100% efficacy from the combination. Others who fall along the diagonal would have little or no added benefit from combination therapy compared to single agent approaches. A cluster of points reveals an incremental benefit of ~30% for combination therapy, while another cluster gets a smaller benefit. A few patients had TMZ values <0 due to mismatch repair deficiency. The addition of lomustine to TMZ would be deleterious compared to lomustine alone for some patients who are above and to the left of the diagonal(3B)
Discussion

As a rule, the benefits of chemotherapy are unevenly distributed among patients classified as having the same disease. Aside from quoting median survival and considering clinical variables (e.g., age, sex, performance status, and residual disease burden), for individual patients oncologists are at a loss to predict the magnitude of benefit of a particular chemotherapy strategy before treatment. Thus, clinical management follows the same assumptions that lead to clinical trial design and recruitment, namely that for the sake of study all m-MGMT patients are considered the same. But in time, patients classified as having the same disease have divergent outcomes, retrospectively making the assumption of sameness naive. By contrast, biosimulation promises to identify the anterior probability of treatment benefit thereby allowing physicians to tailor their clinical decision making for each patient.

In the case of TMZ and lomustine, 35–48% of m-MGMT patients would be predicted to get a major benefit from combination treatment compared to conventional TMZ or the alternative of single agent lomustine, perhaps justifying the inconvenience and extra toxicity. The remainder would be predicted to have either a negligible benefit or one small enough that it might be difficult to justify considering the limited therapeutic index for some patients. With regard to the question of concurrent versus sequential therapy, some patients had relatively modest effects from each single agent, but apparent synergy when the agents were combined, thus favoring combination therapy over a sequential approach. In other circumstances, when the efficacy of both drugs was relatively high and the combination offered relatively little incremental benefit, sequential therapy would seem to be more appropriate. For some patients in this cohort, lomustine was predicted to have better efficacy as a single agent compared to TMZ, while the opposite was observed for another subgroup. One of the most surprising revelations of this study is that TMZ was predicted to cause disease progression rather regression for some and a decremental or anti-therapeutic effect when added to lomustine in 15% of patients. While these findings certainly reflect patient selection in this cohort, the results suggest caution is needed about generalizing positive conclusions from NOA-09 to individual patients.

Many other signaling pathways besides MGMT impact the efficacy and differential sensitivity to these agents.

Fig. 4 Biosimulation scenarios. Horizontal bars represent a measure of $T_{eff}$ for T: TMZ, L: lomustine, and T+L: TMZ and lomustine. A TMZ is highly efficacious, superior to lomustine, and the addition of lomustine adds little value; B modest efficacy exists for both TMZ and lomustine, but the combination achieves >99% efficacy; C lomustine is superior to TMZ; TMZ has no efficacy, and in combination detracts slightly from the benefit of lomustine alone; D lomustine is highly efficacious, superior to TMZ, and TMZ adds little incremental benefit.
suggested that we should fight against the wish for simplicity and the preference for single biomarker rules. Biosimulation demonstrates that the complexity of signaling pathway dysregulation contributes to vast heterogeneity of drug response in this population. In the pathway analysis, a confluence of abnormalities involving NF-κB, hedgehog pathway activation, and MMRD generated a lack of TMZ benefit. On the other hand, HRD, base excision repair deficiency, MMRD, and epigenetic dysregulation contributed to lomustine’s predicted superiority for a subset of patients. Interestingly, MMRD, KMT2A-D loss, and/or EP300 loss of function mutations or deletions produced opposite effects conferring TMZ resistance and lomustine sensitivity in the same patient, thus accounting for lomustine superiority over lomustine for a subgroup of patients. By contrast, HRD and IDH1 mutations conferred sensitivity to both TMZ and lomustine. Interestingly, all the IDH1-mutated patients in this analysis were predicted to have a synergistic benefit from the combination treatment. However, for the majority of patients the co-occurrence of multiple genomic abnormalities creates an otherwise unpredictable mixture of drug responsiveness and resistance resulting in quite different treatment propositions in the clinic. As a result, the uniqueness of each GBM challenges the generalized conclusions about combination chemotherapy and creates a necessity for deeper more comprehensive molecular diagnosis that embraces the complexity of each patient’s disease and its potential divergence from generalized clinical trial conclusions.

Computational biological modeling affords not only an individualized, predictive measure of benefit, but also a quantitative one that simplifies our approach to the patient and overcomes the intrinsic complexity of deconvoluting multiple complex and potentially conflicting signaling pathway inputs. Remarkably, biosimulation embraces the uniqueness (N-of-1) and the complexity in each patient’s cancer. The current study predicts that immense variety exists in the benefit of TMZ and lomustine as single agents as well as in the magnitude of incremental benefit for adding the second drug. For the combination, biosimulation predicts the range of anticipated benefits extends from achieving more than 99% efficacy against the disease to nothing at all, thereby forging an imperative either to implement or shun the combination strategy. In effect, lomustine plus TMZ is essential medicine for some, but of no benefit at all for others, potentially much better or much worse than the average results reported in NOA-09. For a sizable population where the benefit of treatment falls between the extremes, biosimulation fosters an individualized benefit-risk definition that facilitates an informed discussion of therapeutic index, replacing bias and arbitrary opinion with personalized predictive scoring. Rather than risking under-treatment for the sake of safety or over-treatment so as not to miss the possibility for a superior outcome, biosimulation promises to empower neurooncologists to choose the most appropriate option based on the deepest understanding of each patient’s unique disease characteristics.

Our inability to biosimulate every patient with m-MGMT GBM represents a limitation of this approach. Approximately one-quarter of the patients in this study could not be modeled because of an insufficient number of genomic inputs, issues related to disease induction, or inability to achieve a steady state. Additionally, gaps exist in the model created by unknown consequences of genomic abnormalities which have yet to be elucidated by the research community. Implicitly, the success of any model is only as good as the completeness of the knowledge it is based on. While the CBM used in this study continues to evolve, we acknowledge the possibility that predicted outcomes of the patients who were not included in the analysis might have swayed the relative size of the subgroups identified in the study.

Another criticism of this work is that biosimulation awaits prospective clinical validation. This criticism conceals the viewpoint that aside from MGMT, the results of molecular profiling have no role to play in the management of the glioblastoma patient. Nevertheless, the proliferation of insights into the mechanisms of resistance and responsiveness, suggest this view is increasingly untenable. In fact, biosimulation is based on a scientific literature that includes many insights that are already commonplace and as such have the status of “common sense.” The association of IDH1 mutations with TMZ responsiveness, MMRD with temozolomide failure, and the favorable impact of HRD on chemotherapy response represent examples of this. Other scientific insights are less known in clinical circles, such as the impact of HOXA10 amplification, Hedgehog pathway or NF-κB activation on TMZ failure. The integration of both commonly known and unfamiliar insights into a biosimulation model bridges the chasm between the knowledge base of cancer biology and the clinic, and vastly simplifies the labor required to assess the significance of multiple genomic findings at the point of care. We do not disagree that the model used in this study should have prospective validation in a randomized cohort who received combination therapy versus single agent chemotherapy. Rather, we propose that there is an imperative to implement knowledge buried in the cancer biology literature. The consequences for diverse patient management when that knowledge is applied create urgency to complete this validation as soon as possible. If confirmed, neurooncologists would be able to inaugurate a new era of replacing the one size-fits-all decision making and the molecular naivete of the current status quo with a computational tool that maximizes the benefits of drug resources already at hand.

In the era of comprehensive molecular diagnosis, it is likely that more effective personalized clinical management can be
accomplished. The findings of this study suggest that the best therapy available is not represented by a single approach applied to all patients, but is a matter of tailoring the treatment to the molecular underpinnings in each individual’s cancer. In the patient-centric world of molecular diagnosis, the best treatment is not a winner-take-all proposition, but a personalized approach derived from deep insights about the biology of each individual’s disease. The Bayesian approach to clinical decisions based on biosimulation creates the possibility of deriving actionable insight from comprehensive molecular diagnosis to fulfill the mission of giving the correct treatment to every patient. Lastly, molecular diagnosis often points to novel treatment possibilities for subgroups of patients. These include connecting cancers with HRD or STAG2 deficiency with PARP inhibitors, epigenetic dysregulation with histone deacetylase or EZH2 inhibitors, and DNA checkpoint abnormalities with ATM or ATR inhibitors, to name a few. The refinement of patient selection for the next generation of clinical trials based on deep molecular interrogation and comprehensive signaling pathway modeling promises greater success than has been part of the neuro-oncology journey so far. As such, biosimulation provides a practical solution for immediate patient care, but also the opportunity to evolve the armamentarium beyond conventional cytotoxic therapy and illuminate the next steps in the creation of individualized precision therapy for glioblastoma.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s11060-021-03780-0.

Author contributions Conception of the study, data analysis, and writing of the Abstract, Background, Results, and Discussion Sections: MPC. The Cellworks co-authors generated the data and wrote the Methods and Supplementary sections: AP, AA, RP, SR, DAL, KGGR, SB, AP, PN, VI, AA, PG, LB, SK, NRC, SK.

Funding Internal funds were used for expenses associated with this study. Cellworks Group Inc. provided computational biology model testing for patients with internal funding.

Declarations

Conflict of interest Dr. Castro has accepted employment at Cellworks. He provides consultation services to Exact Sciences and Caris Life Sciences, and reports speakers honoraria from Guardant health. Members of Cellworks group are employed by Cellworks.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Stupp R, Warren R, Mason P, van den Bent WP et al (2005) Radiotherapy plus concomitant adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996
2. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M et al (2005) MGMT gene silence and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997–1003. https://doi.org/10.1056/NEJMoa043331 (PMID: 15758010)
3. Herrlinger U, Rieger J, Koch D et al (2006) Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J Clin Oncol 24(27):4412–4417. https://doi.org/10.1200/JCO.2006.06.9104
4. Herrlinger U, Tzaridis T, Mack F et al (2019) Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet 393(10172):678–688. https://doi.org/10.1016/S0140-6736(19)31791-4
5. Das S, Sahgal A, Perry JR (2020) Commentary: lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Front Oncol 10:66. https://doi.org/10.3389/fonc.2020.00066
6. Bredel M, Bredel C, Juric D (2006) Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas. J Clin Oncol 24:274–287
7. Zhang J, Stevens MF, Laughton CA, Madhusudan S, Bradshaw TD (2010) Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications. Oncology 2006(78):103–114
8. Nguyen SA, Stechishin OD, Lchman HA (2014) Novel MSH6 mutations in treatment-naive glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation. Clin Cancer Res 20:4894–4903
9. Agnihotri S, Gajadhar AS, Ternamian C (2012) Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. J Clin Invest 122:253–266
10. Caporali S, Falcinelli S, Starace G, Russo MT, Bonmassar E, Jiricny J, D’Atri S (2004) DNA damage induced by temozolomide signals to both ATM and ATR: role of the mismatch repair system. Mol Pharmacol 66(3):478–491
11. Johannessen TC, Prestegarden L, Grudic A, Hegi ME, Tysnes BB, Bjerkvig R (2013) The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells. Neuro Oncol 15(3):269–278. https://doi.org/10.1093/neuonc/no301
12. Montaldi AP, Godoy PR, Sakamoto-Hejo ET (2015) APE1/REF-1down-regulation enhances the cytotoxic effects of temozolomide in a resistant glioblastoma cell line. Mutat Res Genet Toxicol Environ Mutagen 793:19–29. https://doi.org/10.1016/j.mrgentox (Epub 2015 Jun 5)
13. Nadkarni A, Shrivastav M, Mladek AC et al (2012) ATM inhibitor KU-55933 increases the TMZ responsiveness of only inherently
14. Melamed JR, Morgan JT, Ioele SA, Gleichorn JP, Sims-Mourtada J, Day ES (2018) Investigating the role of Hedgehog/GLI1 signaling in glioblastoma cell response to temozolomide. Oncotarget, 9: 27000–27015. Retrieved from https://www.oncotarget.com/article/25467/

15. Munoz JL, Rodriguez-Cruz V, Walker ND, Greco SJ, Rameshwar P (2015) Temozolomide resistance and tumor recurrence: Halting the Hedgehog. Cancer Cell Microenviron 2(2):e747. https://doi.org/10.14800/ccm.747

16. Avci NG, Ebrahimzadeh-Pustchi S, Akay YM et al (2020) NF-κB inhibitor with temozolomide results in significant apoptosis in glioblastoma via the NF-κB(p65) and actin cytoskeleton regulatory pathways. Sci Rep 10:13352. https://doi.org/10.1038/s41598-020-70392-5

17. Yu X, Wang M, Zuo J et al (2019) Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway. Life Sci 236(1):116917. https://doi.org/10.1016/j.lfs.2019.116917

18. Lee ES, Ko KK, Joe YA, Kang SG, Hong YK (2011) Inhibition of STAT3 reverses drug resistance acquired in temozolomide-resistant human glioma cells. Oncol Lett 2:115–121

19. Wang X, Jia L, Jin X (2015) NF-κB inhibitor reverses temozolomide resistance in human glioma TR/U251 cells. Oncol Lett 9:2586–2590

20. Kim JW, Kim JY, Kim JE, Kim SK, Chung HT, Park CK (2014) HOXA10 is associated with temozolomide resistance through regulation of the homologous recombinant DNA repair pathway in glioblastoma cell lines. Genes Cancer 5(5–6):165–174. https://doi.org/10.18632/genesandcancer

21. Diao PY, Li SX, Peng J et al (2020) Overexpression of EP300-interacting inhibitor of differentiation 3 predicts poor prognosis in patients with glioblastoma multiforme. Int J Clin Exp Pathol 13(5):979–988

22. Ahluwalia MS, Watson D, Kapoor S et al (2020) Superior therapy response predictions for patients with low-grade glioma (LGG) using cellworks singula: MYCARE-009-04. J Clin Oncol 38(15):2569–2569

23. Wen PY, Watson D, Kapoor S et al (2020) Superior therapy response predictions for patients with glioblastoma (GBM) using cellworks singula: MYCARE-009-03. J Clin Oncol 38(15):519–2519

24. Rahman R, Trippa L, Alden S et al (2020) Prediction of outcomes with a computational biology model in newly diagnosed glioblastoma patients treated with radiation therapy and temozolomide. Intl J of Radiat Oncol Biol Phy. https://doi.org/10.1016/j.ijrobp.2020.05.010

25. Deisboeck TS, Zhang L, Yoon J et al (2009) In silico cancer modeling: is it ready for prime time? Nat Clin Pract Oncol 6:34–42

26. Wen PY, Castro M, Watson D et al (2021) Superior overall survival and disease free survival predictions for patients with glioblastoma multiform (GBM) using Cellworks Singula™ myCare-022-03. J Clin Oncol 39 (suppl 15; abstr 2017)

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.